Highlights
An acceleration in put away withdrawals, combined with the prospect of an anti-austerity social gathering winning the next election, has brought to the fore concerns about a potency Greek exit from the euro zone. Our root case assumption is that under|
Glenmark Pharmaceuticals Ltd - Weak Q1 on tepid growth in US/RoW; Maintain BUY ... EBITDA margins (excluding forex) declined ~500bps to 24.4% on higher employees cost and other expenditure. We continue to be positive on the US business |